David Roman
Stock Analyst at Goldman Sachs
(1.82)
# 3,090
Out of 4,870 analysts
43
Total ratings
34.78%
Success rate
-6.59%
Average return
Main Sectors:
Stocks Rated by David Roman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HQY HealthEquity | Maintains: Neutral | $94 → $104 | $101.21 | +2.76% | 3 | Jun 4, 2025 | |
| BBNX Beta Bionics | Initiates: Neutral | $16 | $15.80 | +1.27% | 1 | May 30, 2025 | |
| PODD Insulet | Initiates: Buy | $380 | $307.67 | +23.51% | 1 | May 30, 2025 | |
| DOCS Doximity | Maintains: Neutral | $80 → $50 | $57.98 | -13.76% | 3 | May 21, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Neutral | $120 → $104 | $91.50 | +13.66% | 2 | May 6, 2025 | |
| TDOC Teladoc Health | Maintains: Buy | $13 → $10 | $7.89 | +26.74% | 4 | May 1, 2025 | |
| GEHC GE HealthCare Technologies | Maintains: Buy | $94 → $82 | $71.16 | +15.23% | 3 | May 1, 2025 | |
| KMTS Kestra Medical Technologies | Maintains: Neutral | $24 → $23 | $16.00 | +43.75% | 2 | Apr 16, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $138 → $154 | $133.26 | +15.56% | 2 | Mar 4, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $42 → $24 | $20.22 | +18.69% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $63 → $71 | $73.25 | -3.07% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $55 | $45.57 | +20.69% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $42 | $29.99 | +40.05% | 3 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $91 → $124 | $150.95 | -17.85% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $384 → $427 | $379.16 | +12.62% | 2 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $90 | $75.32 | +19.49% | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $90 | $102.36 | -12.08% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $500 | $515.09 | -2.93% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $274 | $169.72 | +61.44% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $83 | $85.96 | -3.44% | 1 | May 30, 2024 |
HealthEquity
Jun 4, 2025
Maintains: Neutral
Price Target: $94 → $104
Current: $101.21
Upside: +2.76%
Beta Bionics
May 30, 2025
Initiates: Neutral
Price Target: $16
Current: $15.80
Upside: +1.27%
Insulet
May 30, 2025
Initiates: Buy
Price Target: $380
Current: $307.67
Upside: +23.51%
Doximity
May 21, 2025
Maintains: Neutral
Price Target: $80 → $50
Current: $57.98
Upside: -13.76%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Neutral
Price Target: $120 → $104
Current: $91.50
Upside: +13.66%
Teladoc Health
May 1, 2025
Maintains: Buy
Price Target: $13 → $10
Current: $7.89
Upside: +26.74%
GE HealthCare Technologies
May 1, 2025
Maintains: Buy
Price Target: $94 → $82
Current: $71.16
Upside: +15.23%
Kestra Medical Technologies
Apr 16, 2025
Maintains: Neutral
Price Target: $24 → $23
Current: $16.00
Upside: +43.75%
Abbott Laboratories
Mar 4, 2025
Maintains: Buy
Price Target: $138 → $154
Current: $133.26
Upside: +15.56%
Tandem Diabetes Care
Mar 3, 2025
Maintains: Neutral
Price Target: $42 → $24
Current: $20.22
Upside: +18.69%
Mar 3, 2025
Maintains: Sell
Price Target: $63 → $71
Current: $73.25
Upside: -3.07%
Mar 3, 2025
Maintains: Buy
Price Target: $64 → $55
Current: $45.57
Upside: +20.69%
Feb 26, 2025
Reinstates: Buy
Price Target: $42
Current: $29.99
Upside: +40.05%
Feb 24, 2025
Maintains: Neutral
Price Target: $91 → $124
Current: $150.95
Upside: -17.85%
Jan 30, 2025
Maintains: Neutral
Price Target: $384 → $427
Current: $379.16
Upside: +12.62%
Dec 5, 2024
Maintains: Buy
Price Target: $81 → $90
Current: $75.32
Upside: +19.49%
May 30, 2024
Initiates: Buy
Price Target: $90
Current: $102.36
Upside: -12.08%
May 30, 2024
Initiates: Buy
Price Target: $500
Current: $515.09
Upside: -2.93%
May 30, 2024
Initiates: Buy
Price Target: $274
Current: $169.72
Upside: +61.44%
May 30, 2024
Initiates: Sell
Price Target: $83
Current: $85.96
Upside: -3.44%